Last reviewed · How we verify
NCT07067567
A Study of AK146D1 for Injection in Advanced Solid Tumors
Phase 1 trial testing AK146D1 for injection in Advanced Solid Tumors in 200 participants. Currently enrolling.
5 November 2026
Quick facts
| Lead sponsor | Akeso |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 7 August 2025 |
| Primary completion | 5 November 2026 |
| Estimated completion | 5 May 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- AK146D1 for injection — full drug profile →
Conditions studied
- Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Sponsor
Akeso — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK146D1 for injection in advanced solid tumors.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer.
Ávila-Nieto C, Jung G, Salih HR, Hagelstein I. · · 2026 · PMID 41909703 · DOI 10.3389/fimmu.2026.1794705
Verify or expand the search:
- PubMed search for NCT07067567
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AK146D1 for injection
Trials testing the same drug.
- NCT06929663 — A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors · Phase 1 · recruiting
Other recruiting trials for Advanced Solid Tumors
Currently open trials in the same condition.
- NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
- NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Akeso trials
Trials by the same sponsor.
- NCT07449780 — A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XEL · Phase 3 · not yet recruiting
- NCT07412613 — Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer · Phase 3 · not yet recruiting
- NCT07357220 — A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases · Phase 1, PHASE2 · not yet recruiting
- NCT07436234 — A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis · Phase 2 · not yet recruiting
- NCT07436221 — A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07067567 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Akeso
- Last refreshed: 3 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07067567.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing